Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Melanoma 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Sarcoma, Clear Cell 1Rectal Neoplasms 1Radiation-induced Oral Mucositis 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Platinum-resistant Epithelial Ovarian Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Anatomic Stage I Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 8pembrolizumab 5Paclitaxel 4Capecitabine 4Albumin-Bound Paclitaxel 4Nivolumab 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3sargramostim 2poly ICLC 2fludarabine 2Prednisone 2Oxaliplatin 2Irinotecan 2Hydroxychloroquine 2Erlotinib Hydrochloride 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2temsirolimus 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1rucaparib 1resiquimod 1repotrectinib 1regorafenib 1pralsetinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma × Hydroxychloroquine × Clear all
NCT01506973 2025-07-25

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
119 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01206530 2019-04-18

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Completed
50 enrolled
Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡